Icon Plc (NASDAQ:ICLR – Get Free Report) CEO Barry Edward Balfe sold 382 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $164.07, for a total value of $62,674.74. Following the completion of the transaction, the chief executive officer owned 4,804 shares in the company, valued at approximately $788,192.28. This trade represents a 7.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Icon Trading Down 0.3%
Shares of NASDAQ ICLR traded down $0.47 during midday trading on Tuesday, hitting $165.58. The stock had a trading volume of 656,816 shares, compared to its average volume of 1,388,886. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.23. Icon Plc has a 1-year low of $66.57 and a 1-year high of $203.91. The company has a market capitalization of $12.68 billion, a price-to-earnings ratio of 38.87, a PEG ratio of 6.82 and a beta of 1.21. The company has a fifty day moving average price of $160.91 and a 200 day moving average price of $134.45.
Icon (NASDAQ:ICLR – Get Free Report) last posted its earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.55 by $0.01. Icon had a net margin of 3.99% and a return on equity of 8.02%. The firm had revenue of $2.06 billion during the quarter, compared to the consensus estimate of $2 billion. During the same quarter in the prior year, the company earned $3.26 EPS. The company’s revenue was up 2.3% on a year-over-year basis. On average, analysts predict that Icon Plc will post 9.57 earnings per share for the current year.
Analyst Ratings Changes
Read Our Latest Stock Analysis on ICLR
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. EFG International AG acquired a new stake in Icon during the 4th quarter valued at $27,000. Abound Financial LLC acquired a new position in Icon in the 4th quarter worth $54,000. GAMMA Investing LLC boosted its position in Icon by 21.4% in the 2nd quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock valued at $68,000 after buying an additional 69 shares during the last quarter. Johnson Financial Group Inc. purchased a new position in Icon in the 3rd quarter valued at about $71,000. Finally, Quadrant Capital Group LLC acquired a new stake in shares of Icon during the third quarter valued at about $78,000. 95.61% of the stock is owned by institutional investors and hedge funds.
Icon Company Profile
Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.
Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.
Featured Stories
- Five stocks we like better than Icon
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.
